Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03668340 | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | active not recruiting | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03762733 | Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 |
| NCT04065009 | The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer(IPLA-OVCA) | active not recruiting | Phase 3 | 220 | Karolinska InstitutetOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04497844 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)(AMPLITUDE) | active not recruiting | Phase 3 | 696 | Janssen Research & Development, LLCINDUSTRY | 33 | Sep 28, 2026 | clinicaltrials |
| NCT04541030 | Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies | active not recruiting | — | 241 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04644770 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | active not recruiting | Phase 1 | 144 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04662580 | ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer(ARX517) | active not recruiting | Phase 1 | 183 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04706663 | Precision-Based Genomics in Prostate Cancer | recruiting | — | 2,000 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04789694 | Prehabilitation in Gynaecological Cancer Patients(PHOCUS) | recruiting | Phase 3 | 64 | Charles University, Czech RepublicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05112601 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | recruiting | Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05867251 | Study of AVZO-021 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 430 | Avenzo Therapeutics, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT05956093 | 68Ga-FAPI PET/CT in the Staging of High-Grade Epithelial Ovarian Cancers: A Pilot Study(FAST HOC) | active not recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06031805 | PRostate Olaparib Real World Evidence Study(PROWESs) | active not recruiting | — | 159 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06095089 | A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer | recruiting | Phase 1 | 355 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT06298877 | Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer(FOLERO) | recruiting | N/A | 475 | Sahar SalehiOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06472817 | Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men | enrolling by invitation | — | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06496256 | Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial | recruiting | N/A | 84 | Palette Life Sciences, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07515651 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity(MIDAS-SBRT) | not yet recruiting | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07543757 | Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix(PRIME) | recruiting | — | 500 | Sequenom, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer | not yet recruiting | Phase 3 | 600 | PfizerINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 265 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07836933 | Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL) | not yet recruiting | N/A | 50 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study | not yet recruiting | Phase 2 | 53 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07844304 | CascadeDiagnose Prostate MRI | not yet recruiting | — | 3,000 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01727284 | MR-Guided Cryoablation of Prostate Bed Recurrences | enrolling by invitation | N/A | 200 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02123758 | A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 57 | Aragon Pharmaceuticals, Inc.INDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT02531516 | An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | active not recruiting | Phase 3 | 1,503 | Aragon Pharmaceuticals, Inc.INDUSTRY | 23 | Sep 25, 2026 | clinicaltrials |
| NCT02592317 | A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 23 | Aragon Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT03460977 | A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | recruiting | Phase 1 | 453 | PfizerINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03523442 | A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 | 19 | Janssen Research & Development, LLCINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | recruiting | Phase 1 / Phase 2 | 890 | Regeneron PharmaceuticalsINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03767244 | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy(PROTEUS) | active not recruiting | Phase 3 | 2,517 | Janssen Research & Development, LLCINDUSTRY | 18 | Sep 25, 2026 | clinicaltrials |
| NCT04557059 | A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer(PRIMORDIUM) | active not recruiting | Phase 3 | 691 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT04577833 | A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | active not recruiting | Phase 1 | 136 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT04981119 | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing(BASECAMP-1) | recruiting | — | 500 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | active not recruiting | Phase 3 | 381 | Corcept TherapeuticsINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05715216 | EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer | active not recruiting | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05922930 | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06064149 | The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study | active not recruiting | N/A | 100 | Vivek NarayanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | recruiting | Phase 3 | 1,314 | Merck Sharp & Dohme LLCINDUSTRY | 39 | Sep 25, 2026 | clinicaltrials |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 740 | Daiichi SankyoINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06369610 | Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer | active not recruiting | Phase 2 | 110 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06629779 | A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | recruiting | Phase 3 | 900 | PfizerINDUSTRY | 27 | Sep 25, 2026 | clinicaltrials |
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | recruiting | Early Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 25, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials